Floatz logo

tg6002

Colorectal Neoplasm

Transgenegene_therapyPhase 1/2Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

118 Active assets in the Colorectal Neoplasm cohort.

Asset / SponsorPhaseRating
Eloxatin
Peking University Cancer Hospital & Institute
Phase 4BBB
FLUOROURACILUM
Rutgers, The State University of New Jersey
Phase 4BBB
Capecitabine
Rutgers, The State University of New Jersey
Phase 4BBB
Ferric Carboxymaltose [Ferinject]
Nottingham University Hospitals NHS Trust
Phase 4BBB
Irinotecan
Shanghai Zhongshan Hospital
Phase 4BBB

View all 50 →

Same molecule, other indications

tg6002 is also rated in:

brain cancerDormant
C
Indicative ·
38 / 100
View asset →
digestive system neoplasmDormant
C
Indicative ·
38 / 100
View asset →
glioblastomaDormant
C
Indicative ·
34 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →